Related Experiment Video
Updated: Mar 20, 2026
09:40
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
3.3K
DNMT3a expression pattern and its prognostic value in lung adenocarcinoma.
Ryan Edbert Husni1, Aya Shiba-Ishii2, Shinji Iiyama1
1Doctoral Program in Biomedical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.
Lung Cancer (Amsterdam, Netherlands)
|May 31, 2016
Summary
DNA methyltransferases 3a (DNMT3a) expression is linked to better outcomes in lung adenocarcinoma. High DNMT3a levels correlate with non-invasive types and favorable prognosis, suggesting its potential as a clinical indicator.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- DNA methyltransferases (DNMTs) are crucial in DNA methylation and implicated in cancer pathophysiology.
- DNMT overexpression is noted in lung cancer, but its association with specific pathological features remains unclear.
Purpose of the Study:
- To investigate the correlation between DNMT3a expression patterns and the clinicopathological features of lung adenocarcinoma.
- To determine if DNMT3a expression serves as a prognostic marker in lung adenocarcinoma.
Main Methods:
- Immunohistochemistry (IHC) was performed on 135 lung adenocarcinoma specimens.
- Expression levels were quantified, and ROC curve analysis determined the optimal cut-off score.
- Correlations with clinicopathological features and prognosis were analyzed using chi-squared and Cox proportional hazards models.
Main Results:
- DNMT3a was strongly expressed in 58.5% of cases (79/135).
- Strong expression was observed in 93.8% of non-invasive and 77% of lepidic subtypes of lung adenocarcinoma.
- Weak DNMT3a expression was associated with poorer patient outcomes, and multivariate analysis confirmed DNMT3a as an independent prognostic marker.
Conclusions:
- DNMT3a expression in lung adenocarcinoma is associated with non-invasive types, lepidic subtypes, and a favorable prognosis.
- DNMT3a is an independent prognostic marker for lung adenocarcinoma.
- DNMT3a may serve as a clinical indicator of favorable prognosis, as its absence is linked to tumor progression.
